Neurovalens Overview

  • Founded
  • 2015
Founded
  • Status
  • Private
  • Employees
  • 21
Employees
  • Latest Deal Type
  • Early Stage VC
  • Latest Deal Amount
  • $6.37M
Latest Deal Amount
  • Investors
  • 9

Neurovalens General Information

Description

Developer of non-invasive medical technology designed to treat global health epidemics. The company's technology removes the need for surgical implantation and allows early intervention in the treatment pathway, improving patient lives by reducing costs, reducing risk, and crucially improving the disease pathway, enabling healthcare providers to significantly offer effective health outcomes.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Therapeutic Devices
Other Industries
Other Healthcare Technology Systems
Primary Office
  • 4th Floor
  • 7 James Street South, Antrim
  • Belfast BT2 8DN
  • Northern Ireland, United Kingdom

Neurovalens Timeline

2018201920202021
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Neurovalens Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Early Stage VC 20-Jul-2020 $6.37M 000.00 Completed Generating Revenue
6. Debt - General 15-Oct-2019 00000 00.000 Completed Generating Revenue
5. Early Stage VC 15-Mar-2019 00.000 00.000 000.00 Completed Generating Revenue
4. Product Crowdfunding 07-Oct-2017 00.00 00.00 Completed Generating Revenue
3. Seed Round 19-Jul-2017 00.000 00.00 00.000 Completed Generating Revenue
2. Seed Round 01-Dec-2016 $355K $386K Completed Startup
1. Accelerator/Incubator 27-Oct-2015 $30.7K $30.7K Completed Startup
To view Neurovalens’s complete valuation and funding history, request access »

Neurovalens Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
A Preferred 0,000,000 00.000000 00.00 00.00 00 00.00 00.000
Ordinary 0,000,000 00.000000 00.00 00.00 00 00.00 00.000
Preferred Ordinary 000,000 00.000000 00.0 00.0 00 00.0 0.000
Preferred Ordinary 000,000 00.000000 00.00 00.00 00 00.00 0.000
Preferred Ordinary 480,236 $0.000001 $1.44 $1.44 1x $1.44 4.91%
Ordinary 194,598 $0.000001 $1.44 $1.44 1x $1.44 1.99%
To view Neurovalens’s complete cap table history, request access »

Neurovalens Executive Team (3)

Name Title Board Seat Contact Info
Jason McKeown Co-Founder, Chief Executive Officer & Board Member
Niall Quinn Chief Financial & Operations Officer & Board Member
Paul Mcgeoch Co-Founder & Board Member
To view Neurovalens’s complete executive team members history, request access »

Neurovalens Board Members (9)

Name Representing Role Since
Gaby Salem Wharton Asset Management Board Member 000 0000
Ian Kerr Ph.D Beltrae Partners Chairman 000 0000
James Andrews Techstart Ventures Board Member 000 0000
Jason McKeown Neurovalens Co-Founder, Chief Executive Officer & Board Member 000 0000
Niall Quinn Neurovalens Chief Financial & Operations Officer & Board Member 000 0000
You’re viewing 5 of 9 board members. Get the full list »

Neurovalens Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Neurovalens Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Government of UK Government Minority 000 0000 000000 0
Whiterock Finance Lender/Debt Provider Minority 000 0000 000000 0
Clarendon Fund Managers Venture Capital Minority 000 0000 000000 0
IQ Capital Partners Venture Capital Minority 000 0000 000000 0
Wharton Asset Management Family Office Minority 000 0000 000000 0
You’re viewing 5 of 9 investors. Get the full list »